GDC-0032
| CAS No. | 1282512-48-4 | Cat. No. | BCP09253 |
| Name | GDC-0032 | ||
| Synonyms | Taselisib; RG7604;RG-7604; GDC0032; GDC 0032; | ||
| Formula | C24H28N8O2 | M. Wt | 460.53 |
| Description | GDC-0032 is an orally bioavailable, potent and selective inhibitor of Class I PI3Kα, δ and γ isoforms, with 30 fold less inhibition of the PI3K β isoform relative to the PI3Kα isoform. GDC-0032 inhibits MCF7-neo/HER2 cells proliferation with IC50 of 2.5 nM. The combination of GDC-0032 with tamoxifen enhances the efficacy of tamoxifen in vivo (102%TGI for GDC-0032). GDC-0032 is currently in a phase I clinical trial. | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | PI3K | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.